Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations

Ra Pharmaceuticals Inc. (RARX)

46.68   0.57 (1.24%) 02-14 16:00
Open: 46.16 Pre. Close: 46.11
High: 46.98 Low: 46.06
Volume: 1,022,894 Market Cap: 2195M
Ra Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It discovers and develops therapeutics for the treatment of diseases caused by excessive or uncontrolled activation of the complement system.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 47.021 - 47.352 47.352 - 47.61
Low: 45.438 - 45.791 45.791 - 46.065
Close: 46.221 - 46.765 46.765 - 47.187

Technical analysis

as of: 2020-02-14 4:32:00 PM
Stoxline posted a STRONG BUY today, upgraded from lower rating. Upward movement to be expected.
Target: Six months: 55.25     One year: 64.53
Support: Support1: 46.50    Support2: 46.01
Resistance: Resistance1: 47.30    Resistance2: 55.25
Pivot: 46.62
Moving Average: MA(5): 46.29     MA(20): 46.68
MA(100): 44.01     MA(250): 33.02
MACD: MACD(12,26): -0.14     Signal(9): -0.09
Stochastic oscillator: %K(14,3): 25.58     %D(3): 15.01
RSI: RSI(14): 51.64
52-week: High: 47.55  Low: 18.06  Change(%): 139.3
Average Vol(K): 3-Month: 76290  10-Days: 73961

Price, moving averages and Bollinger Bands

Price and moving averages has closed above its Short term moving average. Short term moving average is currently below mid-term; AND above long term moving averages. From the relationship between price and moving averages; we can see that: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.
RARX has closed below upper band by 45.6%. Bollinger Bands are 77.9% narrower than normal. The narrow width of the bands suggests low volatility as compared to RARX's normal range. The bands have been in this narrow range for 73 bars. This is a sign that the market may be about to initiate a new trend.

Headline News

Ra Pharmaceuticals Announces Clearance of IND Application for the HEALEY ALS Platform Trial
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Ra Pharmaceuticals, Inc. (Nasdaq:RARX) today announced the U.S. Food and Drug Administration’s (FDA) clearance of the Investigational New Drug (IND) application for the HEALEY ALS Platform Trial for the treatment of amyotrophic lateral sclerosis (ALS). Zilucoplan was selected as one of the first clinical candidates to be evaluated in this platform trial for ALS led by the Sean M. Healey & AMG Center for ALS at Mass General. “We are pleased that the FDA has

The Daily Biotech Pulse: Second Time's The Charm For Sarepta, Pfizer's Xeljanz Snags Third Approval, NewLink Genetics Rejects Competing Offer
The following is a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks that hit 52-week highs on Dec. 12.) Allergan plc (NYSE: AGN ) Amgen, Inc. (NASDAQ: AMGN ) (received approval for its bone-building osteoporosis drug in the U.S.) Aprea Therapeutics Inc (NASDAQ: APRE ) Aptose Biosciences Inc (NASDAQ: APTO ) Aurinia Pharmaceuticals Inc (NASDAQ: AUPH ) Avenue Therapeutics Inc (NASDAQ: ATXI ) (submitted the NDA for intravenous tramadol for the management of moderate to moderately severe pain in adults in a medically supervised health care setting) Bausch Health Companies Inc (NYSE: BHC ) (reacted to upgrade to Overweight rating by JPMorgan) BioNTech SE – ADR (NASDAQ: BNTX ) Bio-Rad Laboratories, Inc. Class A (NYSE: BIO ) Boston Scientific Corporation (NYSE: BSX ) Bristol-Myers Squibb Co (NYSE: BMY ) Deciphera Pharmaceuticals Inc (NASDAQ: DCPH ) Eidos Therapeutics Inc (NASDAQ: EIDX ) ESSA Pharma Inc (NASDAQ: EPIX ) Flexion Therapeutics Inc (NASDAQ: FLXN ) Forty Seven Inc (NASDAQ: FTSV ) Globus Medical Inc (NYSE: GMED ) (reacted to upgrade to Overweight by Wells Fargo Securities) Gossamer Bio Inc (NASDAQ: GOSS ) Hologic, Inc.

Financial Analysis

Growth measures the growth of both a company's revenue and net income. it tells investors how fast a company is growing.
Profitability measures a company’s ability to generate earnings as compared to its expenses and other relevant costs.
Solvency measures a company's ability to meet its long-term debts. Acceptable solvency ratios will vary from industry to industry.
Efficiency measures the strength of a company's return on invested capital. It can identify business that are better managed or not.
Click here to get more fundamental analysis.
Tweet this page Share on Facebook
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ Global Market
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. (M) 47.15
Shares Float (M) 35.72
% Held by Insiders 4.05
% Held by Institutions 93.85
Shares Short (K) 4100
Shares Short P. Month (K)

Stock Financials

EPS -2.000
Book Value (p.s.) 6.240
PEG Ratio
Profit Margin
Operating Margin -1560.18
Return on Assets (ttm) -26.8
Return on Equity (ttm) -43.9
Qtrly Rev. Growth
Gross Profit (p.s.) 0.053
Sales Per Share
EBITDA (p.s.) -1.777
Qtrly Earnings Growth
Operating Cash Flow (M) -70.82
Levered Free Cash Flow (M) -42.59

Stock Valuations

P/E -23.34
P/E Growth Ratio 0.01
P/BV 7.48
P/S 359.07
P/CF -31.08

Dividends & Splits

Dividend Yield
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
Forward Dividend
Last Split Date
Last Split Ratio -1e+010
7 Binary Options
Your Ad Here
Stock Chart
Stoxline Lite
Stoxline Pro
Option Calculator
(c) 2006-2019 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.